Marshall Wace, LLP Freeline Therapeutics Holdings PLC Transaction History

Marshall Wace, LLP

  • $78.4 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$0.92 - $2.03 $101,832 - $224,694
-110,687 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$1.97 - $3.45 $483,514 - $846,764
-245,439 Reduced 68.92%
110,687 $218,000
Q3 2021

Nov 15, 2021
BUY
$3.04 - $8.9 $1.08 Million - $3.17 Million
356,126 New
356,126 $1.23 Million

Others Institutions Holding FRLN

# of Institutions
1
Shares Held
30.1K
Call Options Held
0
Put Options Held
0
View Full List

About Freeline Therapeutics Holdings plc

FRLN Quotes by TradingView
  • Ticker FRLN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,972,300
  • Description
  • Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...
More about FRLN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email